Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Carmat Heart Sale in 2-5 Years, CEO Tells France Info

(Corrects Cadudal’s title in first paragraph in story published yesterday.)

Jan. 6 (Bloomberg) -- Carmat SAS, whose artificial heart was implanted in a patient for the first time last month, sees the commercialization of the device in “two-to-five years,” Chairman Jean-Claude Cadudal said in an interview on France Info Radio.

The patient who got the implant on Dec. 18 is “doing as well as is possible,” after an operation “of such gravity,” Cadudal told the radio station.

Three more such implants are planned in France, the executive said.

He said the four implants would be the basis for seeking certification for the device in Europe to allow it to be sold commercially. The company would need similar approvals in the U.S., he said.

To contact the reporter on this story: Vidya Root in Paris at vroot@bloomberg.net

To contact the editor responsible for this story: Vidya Root at vroot@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.